

Lorlatinib B7461001

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects




Other adjustments



Lorlatinib B7461001

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies  
Therapeutic Indication: As monotherapy is indicated for the treatment of adult patients with ALK+ advanced NSCLC whose disease has progressed after alectinib or ceritinib as the first ALK TKI therapy; or crizotinib and at least one other ALK TKI  
Experimental Arm: Lorlatinib  
Control Arm: Single arm



